Product image of Omacor (Omega-3-Acid Ethyl Esters 90) supplied by GNH India

Omacor

Active Ingredient:
Omega-3-Acid Ethyl Esters 90
Origin:
EU

Omacor (Omega-3-Acid Ethyl Esters 90)

Omega-3-acid ethyl esters, the active ingredient in Omacor, is a omega-3 fatty acid presented as a 90% oral formulation for oral use. It is prescribed to lower elevated triglyceride concentrations in adults with hypertriglyceridemia and related lipid disorders. Omacor is manufactured under EU pharmaceutical standards and is available only with a prescription.

GNH India supplies Omacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Basf As

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Omacor is an omega‑3 fatty acid medication used to manage disorders of triglyceride metabolism.

  • Hypertriglyceridemia: lowers plasma triglyceride levels to reduce cardiovascular risk.
  • Familial hypertriglyceridemia: helps achieve target triglyceride concentrations in genetically predisposed patients.
  • Secondary hypertriglyceridemia (e.g., diabetes, metabolic syndrome): contributes to overall lipid control alongside lifestyle measures.

How It Works

  • Omega-3-acid ethyl esters are hydrolysed to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which inhibit hepatic very‑low‑density lipoprotein (VLDL) synthesis and increase the catabolism of triglyceride‑rich lipoproteins, resulting in reduced circulating triglyceride concentrations.

Side Effects

Adverse reactions may occur with Omacor and are categorized by frequency.

Common Side Effects

  • Fish‑oil aftertaste: mild, transient taste disturbance.
  • Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.
  • Diarrhea: loose stools occurring during initial therapy.
  • Belching: occasional eructation with a fishy odor.
  • Flatulence: increased intestinal gas.
  • Mild headache: occasional tension‑type headache.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Allergic reactions: rash, pruritus, or angioedema.
  • Bleeding tendency: prolonged bleeding when combined with anticoagulants.
  • Elevated liver enzymes: transaminase increases indicating hepatic stress.
  • Atrial fibrillation: rare cardiac rhythm disturbances.

Precautions & Warnings

Before initiating Omacor, clinicians should consider several safety measures.

  • Monitor triglyceride levels: assess response and adjust therapy as needed.
  • Assess liver function: obtain baseline and periodic hepatic enzyme tests.
  • Evaluate bleeding risk: review concomitant anticoagulant or antiplatelet use.
  • Counsel on dietary fish intake: avoid excessive omega‑3 consumption from other sources.
  • Review pregnancy and lactation status: weigh potential benefits against unknown risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Omacor may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid)

  • Warfarin or other oral anticoagulants: increased bleeding risk.
  • Antiplatelet agents (e.g., clopidogrel): additive antithrombotic effect.
  • High‑dose vitamin E supplements: potential for enhanced anticoagulation.

Moderate Interactions (Monitor Closely)

  • Statins: monitor for myopathy when combined with high‑dose omega‑3.
  • Fibrates: assess for additive triglyceride‑lowering effect and liver enzymes.
  • Blood pressure medications: observe for modest blood pressure reduction.
  • Other omega‑3 preparations: avoid duplicate therapy to prevent excess dosing.
  • Immunosuppressants: monitor for possible alterations in drug metabolism.

Frequently Asked Questions

Omacor is prescribed to lower high triglyceride levels in adults with hypertriglyceridemia or related lipid disorders. By reducing circulating triglycerides, it helps lower the risk of pancreatitis and may contribute to overall cardiovascular risk management when used with diet and lifestyle changes.

The ethyl ester form is hydrolysed in the gut to EPA and DHA, which suppress hepatic VLDL production and enhance the clearance of triglyceride‑rich particles. This dual action reduces plasma triglyceride concentrations and improves lipid profiles.

The specific dose of Omacor is determined by the prescribing clinician based on the patient’s triglyceride level, response to therapy, and any concomitant medications. Dosage adjustments are made during follow‑up visits to achieve target lipid goals.

Safety data for Omacor in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against any unknown risks before initiating therapy in pregnant or nursing individuals.

To request Omacor, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Omacor belongs to the omega‑3 fatty acid class, offering a distinct mechanism from fibrates or niacin. It is particularly effective for very high triglyceride levels and is often used when patients cannot tolerate or have contraindications to other agents. Clinical choice depends on individual risk profiles and therapeutic goals.

Omacor should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Omacor is taken orally, usually with meals to improve absorption. The capsules are swallowed whole with a full glass of water. Patients should follow the prescriber’s instructions regarding timing and any dietary considerations.

Serious adverse events, although rare, include pancreatitis, severe allergic reactions, significant bleeding especially when combined with anticoagulants, and elevations in liver enzymes. Patients should seek immediate medical attention if they experience severe abdominal pain, unusual bruising, or signs of an allergic response.

Omacor is contraindicated in individuals with known hypersensitivity to omega‑3 fatty acids or any capsule ingredients. Patients with active bleeding disorders, uncontrolled severe liver disease, or those taking multiple high‑dose omega‑3 supplements should avoid use unless specifically directed by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Omega-3-Acid Ethyl Esters 90

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT